Targeting collagen |
|
-
1.
Potential for drug resistance.
-
2.
The complexity in the ECM composition and structure, and the presence of intratumor heterogeneity limit targeted therapy for ECM.
|
[131] [132] [102] |
Degrading ECM |
Deactivating the pro-tumorigenic function of ECM after degradation via proteases. |
|
[133] [134] [135] [107] [108] |
ECM remodeling |
-
1.
Inhibiting the expression of proteins in a variety of pathways leads to a reduction in the metastatic potential of cancer cells, thus blocking metastasis and inhibiting tumor progression.
-
2.
Tumor pathway inhibitors can be used in combination with other agents to achieve better anti-tumor effects.
|
-
1.
Cancer metastasis is tissue-specific, and complex intervention measures are required.
-
2 .
Unpredictable effects, such as immune suppression.
-
3.
More clinical trials specifically on ECM remodeling events are needed.
|
[119] [120] [126] [127] |